Trial Profile
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Voretigene neparvovec (Primary)
- Indications Leber congenital amaurosis
- Focus Adverse reactions
- Sponsors Applied Genetic Technologies Corporation
- 27 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Jun 2017 Planned End Date changed from 1 Dec 2027 to 1 Dec 2017.
- 22 Apr 2016 Results published online in the journal Ophthalmology and will appear in the April print issue of the journal, according to an Applied Genetic Technologies Corporation media release.